|Day Low/High||323.91 / 327.75|
|52 Wk Low/High||249.17 / 388.67|
The biotech giant also raised its 2018 guidance for both revenue and earnings.
U.S. stock futures rise on Tuesday, with solid corporate earnings boosting shares on Wall Street; Alphabet is set to open at a record high after the parent of Google posts a significant earnings beat; AT&T and Verizon highlight Tuesday's earnings calendar.
The Cambridge, Mass.-based biotech is scheduled to unveil its second-quarter results before the market open on July 24.
Positive readings from the biotech giant's Alzheimer's drug could drive the stock to as high as $393.
Jim Cramer is bullish on Target, Biogen Idec, Regions Financial, Lockheed Martin, US Bancorp, BlackRock and more.
Jim Cramer says financial payment companies are the most beloved in the market right now. He explains digitized payment companies. And love.
The biotech and pharmaceutical industries have had some big news in recent weeks. Here's what you should know to stay up-to-date.
Adamis Pharmaceuticals and Pieris Pharmaceuticals are names to watch.
After Friday's surge another look at BIIB is warranted.
The seemingly terrific rationales for strength in these economically sensitive sectors seem glib until the bigger global economic issues get resolved.
Biogen delivered promising results on a new Alzheimer's disease treatment. And investors rewarded the company accordingly.
Here's what you need to know now for Friday, July 6.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending market topics from the floor of the New York Stock Exchange.
Real Money reveals the crucial component Biogen got right in this trial and what it plans for the drug next.
The company's drug showed promising results versus a placebo in a Phase 2 trial.
The history of trying to cure Alzheimer's is full of mistakes and false promises.
Jim Cramer and our other experts discuss bulls and bears, Biogen, and 4 bargain stocks.
Investors might be finally recognizing the hidden value of the firms' drug research and development.
There are issues in the study that are keeping some buyers cautious and causing selling into the early strength.
Since TheStreet Ratings upgrade on May 1, shares of the biotech giant have recovered strongly.
This biotech's weekly chart is very encouraging.
First Trust NYSE Arca Biotechnology Index Fund and iShares Nasdaq Biotechnology ETF look like two ways to catch the rally in Biogen.
My longer-term price target is now $416.
The Duchenne Muscular Dystrophy specialist announces early results that show a gene-based treatment for the debilitating disease may be just two years away.
In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Biogen Inc has taken over the #107 spot from Nielsen Holdings PLC , according to ETF Channel. Below is a chart of Biogen Inc versus Nielsen Holdings PLC plotting their respective rank within the S&P 500 over time (BIIB plotted in blue; NLSN plotted in green): In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending stocks from the floor of the New York Stock Exchange.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.